| Similar Articles |
|---|
 |
Reason
November 2002
Jacob Sullum |
Constant Improvement The secret of DARE's success   |
Reason
January 2004
Renee Moilanen |
Just Say No Again The old failures of new and improved anti-drug education |
The Motley Fool
May 26, 2011
Brian Orelli |
Congress Sets Bad Precedent With AVANIR What happened to free markets? |
The Motley Fool
July 28, 2010
Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage |
The Motley Fool
August 31, 2010
Brian Orelli |
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior. |
Chemistry World
November 18, 2010
Ned Stafford |
New drug pricing rules in Germany The law was approved on 11 November and will take effect from 1 January as part of an effort to rein in exploding costs for Germany's massive public health insurance system. |
The Motley Fool
April 26, 2011
Brian Orelli |
There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost. |
CRM
December 2012
Marshall Lager |
Smarten Up Arm graduates with skills that matter. Studentforce is an extremely clever system built on the Force platform. It is nothing less than a complete educational management system. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
August 17, 2010
Brian Orelli |
Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard. |
The Motley Fool
July 12, 2010
Ryan McBride |
Synta Pharma CEO Trumpets New Top Cancer Drug Synta Pharmaceuticals has been climbing back from one of the Boston area's highest-profile clinical trial failures of 2009. |
Chemistry World
April 27, 2011
Carol Stanier |
Drug cocktails greater than the sum of their parts Canadian scientists have shown that combining an antibiotic that is past its prime with other drugs can give it a new lease of life. |
The Motley Fool
December 10, 2010
Brian Orelli |
Was This Drug Destined for Failure? Pfizer announces that it's pulling Thelin off the market, and withdrawing the marketing application with the Food and Drug Administration, because a new side effect was discovered. |
The Motley Fool
July 30, 2010
Brian Orelli |
A Faster Pathway to Drug Approvals A thinktank called the Pacific Research Institute has proposed letting drugs approved by the European Medicines Authority onto the market in the U.S. before the Food and Drug Administration has approved the drugs. |
The Motley Fool
February 14, 2011
Brian Orelli |
This Biotech Is Heating Up Biosante Pharmaceuticals was up more than 9% at one point today after the company said the independent Data Monitoring Committee believed Biosante's female sexual dysfunction drug, LibiGel, was safe enough to allow the trial to continue. |
The Motley Fool
December 2, 2010
Brian Orelli |
An Ounce of Prevention Gets Shot Down An FDA panel shoots down Merck's and Glaxo's prostate drugs. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
Chemistry World
March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
The Motley Fool
February 10, 2010
Brian Orelli |
Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause. |
The Motley Fool
June 29, 2010
Brian Orelli |
The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting. |
The Motley Fool
March 31, 2011
Brian Orelli |
Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones? |
The Motley Fool
May 7, 2010
Brian Orelli |
Drug Companies: Recession-Resistant, but Government-Proof? Greece decided to take action and forced drugmakers to reduce drug costs by an average of 21.5%. Investors need to think twice before making the seemingly sure bet on pharmaceutical companies. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
December 3, 2010
Travis Hoium |
Orexigen Therapeutics Shares Plunged: What You Need to Know Shares of biopharmaceutical company Orexigen Therapeutics fell 10% today after a Food and Drug Administration announcement. |
The Motley Fool
February 16, 2010
Brian Orelli |
Merck Gets a Pass, for Now Its first quarter looks promising, but not as good as could be hoped. |
The Motley Fool
October 26, 2010
Brian Orelli |
Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth. |
The Motley Fool
September 20, 2010
Brian Orelli |
Potential Blockbuster, No Me-Too About It A diabetes-fighting duo do it right this time. |
The Motley Fool
September 15, 2010
Brian Orelli |
Drug Approved. Now Let's Sell This Baby! With ink still wet on its FDA approval, Savient continues its plan to find a buyer. |
Chemistry World
July 16, 2010
Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
The Motley Fool
March 11, 2010
Brian Orelli |
FDA Still Has a Bone to Pick With These Drugmakers Osteoporosis drugs remain under the microscope. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
April 28, 2011
Brian Orelli |
Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval. |
Chemistry World
March 11, 2010
Simon Hadlington |
Thalidomide Binding Protein Revealed Scientists in Japan believe they have revealed one of the key molecular targets that binds to the drug thalidomide to cause birth defects. |
The Motley Fool
September 23, 2010
Brian Orelli |
A Blockbuster in Due Time Novartis' new multiple sclerosis drug, Gilenya, isn't king yet. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
Fast Company
June 2013 |
Pop Quiz: Which Channel Is Getting Kidified? NBCUniversal partially owns KidsCo, a children's TV network that airs globally (but not in the U.S.). This month, it begins a cute experiment in brand extensions. |
Fast Company
Evie Nagy |
Tiger Moms, Take Note: How Science Can Make You A Better Parent Fast Company spoke with New York University sociologist Dalton Conley about the principles in his new book on parentology, the importance of improvisation, and what parents can do to learn how to not freak out. |
Fast Company
November 2013 |
Want to Be the Next Zuck? Step Right Up for Your Free Idea We are offering an idea each month for much needed innovative products like a never-ending series of enrichment modules to inspire and educate kids. |
Fast Company
Laura Vanderkam |
One Week Without The Kids Having kids home sick from day care will cut into work time. But life happens to people without kids, too. |
The Motley Fool
June 25, 2010
Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. |
The Motley Fool
August 26, 2010
Brian Orelli |
Drug Prices Up, but Don't Read Too Much Into It AARP is out with its annual report on the cost of medications, and it's more of the same: bad news if you're a consumer, but good news if you're invested in drugmakers. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
March 3, 2010
Brian Orelli |
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. |
The Motley Fool
May 5, 2010
Brian Orelli |
Doubled Revenue, but Not High Growth An acquisition and some rearrangements make Merck's revenue line sound better than it is. |
The Motley Fool
February 25, 2010
Brian Orelli |
An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies. |
The Motley Fool
January 7, 2010
Brian Orelli |
Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered. |
